Modified Huang-Lian-Jie-Du Decoction (MHLJDD) for Atopic Dermatitis in Children

Last updated: July 6, 2023
Sponsor: Chinese University of Hong Kong
Overall Status: Active - Recruiting

Phase

1/2

Condition

Eczema (Atopic Dermatitis - Pediatric)

Allergies & Asthma

Hives (Urticaria)

Treatment

Modified Huang-Lian-Jie-Du Decoction (MHLJDD)

Placebo

Clinical Study ID

NCT05613062
AD HLJDD study
  • Ages 4-17
  • All Genders

Study Summary

The study aims to evaluate the clinical efficacy of Chinese medicine (CM) for the treatment of subacute and chronic Atopic Dermatitis (AD) patients when compared to the placebo control by examining the clinical symptoms.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age of 4 to 17 (Chinese only);
  • With EASI ≥ 10;
  • Subacute and chronic atopic dermatitis presenting with dry, scaly, erythematouspapules and plaques; and
  • Provide a written informed consent form (signed by one of their parents)

Exclusion

Exclusion Criteria:

  • History of allergy to Chinese medicines;
  • AD with Yang deficiency in syndrome differentiation, such as pale looking, alwaysfeeling cold, fatigue, chronic diarrhea with loose stool, urinary disorders such asurinary difficulty, excessive urination or incontinence
  • Known overt bacterial infections in the skin;
  • Known pregnancy;
  • Known severe medical conditions, such as cardiovascular, liver or renal dysfunction orDiabetes Mellitus;
  • Having used oral corticosteroids, oral antibiotics, other immunosuppressive or anypreparation of oral herbal medicines for the treatment of AD in the past month;
  • Having been diagnosed with scabies, allergic contact dermatitis, seborrheic dermatitisor psoriasis;
  • Has taken anti-coagulant or anti-platelet drugs in the past month;
  • Has taken any probiotics, prebiotics in the last month; and
  • Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Study Design

Total Participants: 20
Treatment Group(s): 2
Primary Treatment: Modified Huang-Lian-Jie-Du Decoction (MHLJDD)
Phase: 1/2
Study Start date:
April 11, 2023
Estimated Completion Date:
June 30, 2024

Study Description

This is a parallel, randomized, placebo-controlled, double-blind pilot study. The subjects will come for a screening visit at week 0 (baseline), then at week 6±3 days, week 12±3 days and week 16±4 days for Chinese medicine practitioner (CMP) investigators' assessments (Fig 1). Eczema Area and Severity Index (EASI), Children's dermatology life quality index (CDLQI), and Patient-Oriented Eczema Measure (POEM) will be assessed and filled up at different time points. Eligible subjects will be randomly allocated to the treatment group receiving oral CM granules or the placebo control group receiving oral placebo granules for 12 weeks, and then be followed up 4 weeks after the treatment.

Connect with a study center

  • School of Chinese Medicine

    Hong Kong,
    Hong Kong

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.